The Schall Law Firm Is Looking Into Whether Customers Bancorp Inc Committed Securities Fraud And Investors With Losses Should Reach Out

LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Customers Bancorp, Inc. ("Customers Bancorp" or "the Company") (NYSE:CUBI) for violations of the securities laws. The investigation focuses on whether the Company issued false […]

Sprinklr Inc Is Being Sued For Possible Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sprinklr, Inc. ("Sprinklr" or "the Company") (NYSE:CXM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the

Globus Medical, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Shareholder Participation

LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or "the Company") (NYSE:GMED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or

The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Orthofix Medical Inc.

LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by

Franklin Resources, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Shareholder Participation

LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Franklin Resources, Inc. ("Franklin" or "the Company") (NYSE:BEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or

STMicroelectronics NV Is Being Sued For Violating Securities Laws And Shareholders Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a category motion lawsuit against STMicroelectronics N.V. ("STMicroelectronics" or "the Company") (NYSE:STM) violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S.

The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Methode Electronics Inc

LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Methode Electronics, Inc. ("Methode" or "the Company") (NYSE:MEI) violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the

The Schall Law Firm Encourages Investor Participation In An Inquiry Into ARC Document Solutions Inc For Possible Securities Fraud

LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in ARC Document Solutions, Inc. ("ARC Document Solutions" or "the Company") (NYSE:ARC) for potential breaches of fiduciary duty on the part of its directors and

The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Verve Therapeutics, Inc.

LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by

Scroll to Top